1. The RET Tyrosine Kinase Receptor Targets a Diverse Spectrum of Intracellular Signaling Pathways {#sec1}
==================================================================================================

*RET* (Rearranged during Transfection) encodes a membrane receptor tyrosine kinase (RTK) composed of four extracellular cadherin-like motifs and a cysteine-rich region, a transmembrane portion, and an intracellular domain with tyrosine kinase activity \[[@B1]\]. The RET signaling pathways are outlined in ([Figure 1](#fig1){ref-type="fig"}). RET signals through a ligand/coreceptor/RET multiprotein complex instead of the usual receptor/ligand binding. To date, several ligands of the glial-derived neurotrophic factor (GDNF) family, which include GDNF, artemin, neurturin, and persephin and a family of GPI-linked RET coreceptors (GFR1-4), have been identified \[[@B2]\]. The formation of ligand/coreceptor and RET complexes results in RET dimerization and triggers autophosphorylation at intracellular tyrosine residues. Phosphorylated tyrosine 687 (Y687), serine 696 (S696), Y752, Y791, Y806, Y809, Y826, Y864, Y900, Y905, Y928, Y952, Y981, Y1015, Y1029, Y1062, Y1090, and Y1096 constitute docking sites for numerous intracellular adaptor proteins such as RAC1-guanine exchange factor (GEF) \[[@B3]\], growth factor receptor-bound (GRB) docking proteins GRB7/10 \[[@B4]\], chicken Rous sarcoma virus oncogene (c-Src), focal adhesion kinase (FAK) \[[@B5]\], phospholipase C-*γ* (PLC-*γ*) and Src homologue collagen (Shc), insulin receptor substrate 1/2 (IRS1/2), fibroblast growth factor substrate 2 (FRS2), or downstream of kinase 1/4/5 (DOK1/4/5) (reviewed by De Groot et al. \[[@B6]\]).

Phosphorylation of intracellular target proteins activates several downstream pathways which include mitogen-activated protein kinase cascade: rat sarcoma oncogene/rapidly accelerated fibrosarcoma/extracellular regulated kinase 1/2 (RAS/RAF/ERK1/2), the phosphatidylinositol 3-kinase/protein kinase B pathway (PI3K/AKT) \[[@B7], [@B8]\], the c-Jun N-terminal kinase pathway (JNK) \[[@B9]\], p38, enigma extracellular regulated kinase 5 (ERK5), the cAMP-responsive element-binding protein, and the signal transducer and activator of transcription 3 (STAT3) (for a review see Arighi et al. \[[@B10]\] and De Groot et al. \[[@B6]\]. More recently, Gujral et al. \[[@B11]\] have shown that RET mediates direct tyrosine phosphorylation of beta-catenin, which associated with an induction of the WNT pathway, that accounts for a part of RET tumorigenic ability *in vivo* \[[@B11]\].

Many of the above-mentioned intracellular signalling pathways are otherwise known to be general signal transducing pathways targeted not only by RET, but by other RTKs as well. Yet, RET is the main RTK targeted for genetic lesions in thyroid cancer. The transforming ability of activated RET, which was actually on the basis of its isolation as an oncogene \[[@B12]\], could be attributable to the diversity of its signalling which covers several hallmarks of cancer \[[@B13]\].

Increased growth signals and proliferation result from the activation of the RAS/RAF/ERK1/2 cascade and phosphorylation of STAT3 \[[@B14], [@B15]\].

Cell migration is dependent on RET-mediated activation of RAC1 and JNK \[[@B3], [@B16]\], and FAK \[[@B5]\] is also reported to play a role in cell migration and to be required for invasion and metastatic behaviour \[[@B5], [@B17]\].

Inflammation (regarded as the 7th hallmark of cancer \[[@B18]\]) has also been shown to operate as a major component downstream of oncogenic RET mutations. In freshly isolated human thyrocytes, the activation of RET generates a transcriptional program that is similar to that which occurs during inflammation \[[@B19]\] inducing the expression of various inflammatory factors \[[@B19]--[@B21]\]. Furthermore, key protein components of the RET-activated "inflammatory" program were found in tumor specimens taken by biopsy, and larger amounts of these inflammatory molecules were found in the primary tumors of patients with lymph-node metastasis than in primary tumors in the absence of lymph-node metastasis (reviewed in \[[@B22]\]). These and other results (\[[@B23], [@B24]\]; \[[@B25]\]) connect the activation of RET to inflammation.

2. Hereditary MTC-Associated Activating Mutations Cluster at Specific Functional Domains of the RET Receptor Kinase {#sec2}
===================================================================================================================

Overall, as stated before, varied signalling properties, covering multiple hallmarks of cancer, might afford explanation for the ability of RET to transform certain cell types. Nonetheless, the most solid grounds for the significance of RET as a cancer gene come from the fact that, when inherited, an RET germline point mutation alone primes a specific spectrum of tissues to develop endocrine tumors \[[@B26], [@B27]\]. Carriers of RET germline mutations develop hereditary medullary thyroid carcinoma (hMTC) as the first and most common clinical presentation. Along with hMTC, patients present with pheochromocytoma (tumor of the adrenal medulla) and parathyroid adenomas. This syndromic condition is referred to as Multiple Endocrine Neoplasia type 2 (MEN2) \[[@B28]\]. Penetrance for hMTC is near complete, which highlights the critical role of RET activation in the development of MTC and can be further taken to pinpoint RET as a relevant therapeutic target for MTC.

In hMTC, *RET* mutations occur in a specific spectrum of codons and result in gain of function, increased kinase activity, and receptor activation \[[@B29]\]. Mutational hotspots are located at the cysteine-rich region of the extracellular domain and in the intracellular tyrosine kinase domain \[[@B28]\]. The clustering of mutations in hotspots might be explained by the fact that proto-oncogene activation requires changes at residues that specifically interact in specific ways with receptor function, and thus mutations cannot occur in a widespread manner. A comprehensive description of all known germline *RET* variations can be found at the MEN2 RET database ([http://www.arup.utah.edu/database/MEN2/MEN2\_](http://www.arup.utah.edu/database/MEN2/MEN2_welcome)[Welcome](http://www.arup.utah.edu/database/MEN2/MEN2_welcome)). The most common *RET* germline mutations are missense substitutions of extracellular cysteine residues, occurring at cysteine codon 634 in 80% of cases. Cysteine codons 609, 611, 618, 620, and 630 are less frequently affected. Other noncysteine extracellular domain mutations, located at exons 5 and 8, have been detected \[[@B30]\]. Tyrosine kinase domain mutations affect a more varied spectrum of amino acids, and most frequently recurring mutations replace Met918, Val804, Leu790, Tyr791, and Ala883. Less frequently, residues 768, 876, 891, 886, and 912 are affected. Rare mutations found in isolated families have been reported, comprising homozygous mutations \[[@B31]\], duplications \[[@B32]\], and double mutations \[[@B33]\].

Besides the point mutations found in MTC, an alternative somatic genetic event that causes RET activation is found in the papillary type of thyroid carcinoma (PTC). This involves chromosomal translocations between RET and a number of other loci, referred in general as RET/PTC rearrangements, which interestingly occur as alternative events to the V600E somatic BRAF mutation \[[@B34]\].

3. Distinct RET Mutations Determine Different Clinical Presentations of MEN2 and Predict Age of Onset of hMTC {#sec3}
=============================================================================================================

In MEN2 there are consistent genotype/phenotype correlations that underlie aspects such as clinical manifestation, RET activation mechanisms, and disease penetrance, allowing for a mutation-specific classification of MEN2 \[[@B28]\]. In clinical terms, three disease phenotypes can be recognized: MEN2A, MEN2B, and a familial form of medullary thyroid carcinoma (FMTC). MEN2A was found to be associated with substitutions at one of six specific cysteine residues in exons 10 (609, 611, 618, 620) and 11 (630 and 634). MEN2A cysteine mutations give rise to MTC at young age (onset at 5 to 25 years), along with variable expression of pheochromocytoma (50%) and hyperparathyroidism (15--30%) \[[@B28]\]. MEN2B, on the other hand, is mainly caused by a specific missense mutation located at the RET tyrosine kinase domain (Met918Thr), which accounts for 95% of cases \[[@B35]\]. A second tyrosine kinase domain substitution (Ala883Phe) has been detected in a small proportion of MEN2B patients \[[@B36]\]. Additionally, double mutations affecting codons 804 and 805 and 804 and 806 were described in individual MEN2B cases \[[@B33], [@B37]\]. MEN2B kinase domain mutations give rise to a more complex clinical phenotype characterized by an early onset (sometimes \<1 year old) and very aggressive form of MTC, concomitant with pheochromocytoma in 50% of cases and accompanied by other nonneoplastic features, such as mucosal neuromas of the tongue, lips, and eyelids, ganglioneuromatosis of the gastrointestinal tract, thickening of corneal nerves, and Marfanoid habitus \[[@B38]\]. In FMTC the only disease manifestation is MTC, which usually occurs in adult age, with no additional endocrinopathies. *RET* mutations with low clinical expression, involving codons 321, 533, 768, 790, 791, 804, and 891, may be found in these families \[[@B28]\]. Occasionally, patients with these mutations may also develop the MEN2A phenotype, showing that FMTC and MEN2A represent a continuum of clinical expression in a common genetically related disorder \[[@B39]--[@B42]\]. Age-dependent penetrance for MTC in MEN2 is also codon specific, and classification of the risk of developing MTC can be done based on the genotype (reviewed by Raue and Frank-Raue in \[[@B43]\]). This is of clinical relevance because the ideal timing of prophylactic thyroidectomy should take into consideration the balance between the adverse effects of thyroidectomy at early ages and the individual risk of developing MTC. Comprehensive guidelines have been issued by the American Thyroid Association concerning this aspect \[[@B44]\]. In general, RET mutations with a very high risk of producing MTC (risk level D), comprising all the MEN2B mutations, require surgery before 1 year of age. RET mutations at codon Cys634 constitute risk level C and are managed by thyroidectomy before 5 years old. Level B mutations encompass the changes in the remaining extracellular cysteine codons 609, 611, 618, 620, and 630. In these cases, surgery is advised before 5 years old; however it can be postponed until calcitonin level rise. Risk level A accounts for the FMTC mutations, for which surgery before 5 years old is not required and can be delayed until calcitonin levels rise.

4. The Nature of Somatic RET Mutations Influences the Prognosis of Sporadic MTC {#sec4}
===============================================================================

Aside from germline mutations, a somewhat similar spectrum of somatic mutations is observed in about 50 to 60% of the cases with sporadic MTC. A catalogue of somatic mutations can be found at the COSMIC database (<http://www.sanger.ac.uk/genetics/CGP/cosmic/>). The most frequent somatic lesion is the prototypic MEN2B Met918Thr mutation at exon 16, which comprises up to 60% of the mutation positive cases. Moreover, patients in which tumors harbor MEN2B mutations have a higher prevalence and number of lymph node metastases, present more often with multifocal tumors and with persistent disease at advanced stage, indicating that among the sporadic MTCs, cases with somatic MEN2B mutations are associated with the worst prognosis \[[@B45], [@B46]\]. Interestingly, cases with RET mutations at the cysteine cluster have the most indolent course, and those with no RET mutations have an intermediate risk \[[@B46]\].

5. Mutations Activate RET by Distinct Mechanisms and Confer Somewhat Different Oncogenic Signaling Properties {#sec5}
=============================================================================================================

The functional basis for the differences in clinical expression of distinct RET genotypes might be explained by the recognition of mutation-specific mechanisms of activating the *RET* proto-oncogene. Mutations in the extracellular cysteine-rich region result in the replacement of a cysteine residue by another amino acid, subsequently leading to loss of an intramolecular disulfide bond. As a consequence, one cysteine residue becomes available for the formation of an intermolecular disulfide bond, which results in covalently bound receptors that are constitutively active because of ligand-independent receptor dimerization \[[@B29]\]. These mutations commonly associate with MEN2A and FMTC. In contrast, the intracellular MEN2B-specific mutations and other tyrosine kinase domain mutations affect receptor activation in a totally different way. By altering the conformation of the catalytic core of the tyrosine kinase domain they increase catalytic activity and alter the spectrum of intracellular substrates, resulting in remarkable changes of the signalling properties of the receptor \[[@B29]\].

These observations highlight that distinct clinical presentations can arise from differences in the RET activation mechanism and the corresponding output in terms of oncogenic signalling. However, not much is known about the specific differences in signalling properties of the different RET mutants. Studies have shown that wild-type and mutated RET display differences in the autophosphorylation levels of docking sites, which are likely to lead to differential activation of downstream cascades \[[@B47]\]. Support for this paradigm comes from evidence that there are marked differences between MEN2A and MEN2B mutations in terms of their capacity for downstream PI3K/AKT activation. This pathway seems to be more active in MEN2B than in MEN2A \[[@B7]\], and this difference might be attributed to an enhanced autophosphorylation of Y1062 caused by the MEN2B mutation \[[@B48]\].

Another example concerns RET-induced activation of STAT3. The MEN2A mutation Cys634Arg activates STAT3 independently of Janus tyrosine kinases (JAKs) \[[@B15]\]. However, the FMTC mutants, Tyr791Phe and Ser891Ala, seem to do so through a different route and need the involvement of Src and JAKs in order to constitutively activate STAT3 \[[@B49]\].

Thus, on the basis of the above-mentioned evidence that distinct signalling properties are displayed by RET mutants, it is conceivable that different sensitivity to the action of tyrosine kinase inhibitors can occur due to the potentially different conformations of the receptor in each of the RET mutants.

6. RET-Targeting Tyrosine Kinase Inhibitors {#sec6}
===========================================

The small molecule tyrosine kinase inhibitors (TKIs) mechanism of action is based on the principle that sterically blocking the ATP-binding pocket results in impaired phosphorylation activity, inhibits signal transduction, and prevents activation of intracellular signalling pathways relevant to tumor growth and angiogenesis.

The finding of various compounds ([Table 1](#tab1){ref-type="table"}) capable of inhibiting oncogenic RET (mutated or rearranged), such as PP1 and PP2 \[[@B50]\], ZD6474 (Vandetanib) \[[@B51]\], RPI-1 \[[@B52]\], CEP-701, CEP-751 \[[@B53]\], Imatinib \[[@B54]\], Sunitinib (SU5416, SU11248) \[[@B55]\], Gefitinib \[[@B56]\], Sorafenib (BAY 43-9006) \[[@B57]\], Motesanib (AMG706) \[[@B58]\], Axitinib (AG013736) \[[@B59]\] and XL 184, has brought further clinical relevance to the classification of the pharmacological sensitivity of RET mutants, as metastatic MTC is the most common cause of death in patients with MEN2 \[[@B60]\]. In addition, these compounds could find application in radioactive iodine-refractory PTC with RET/PTC rearrangements.

*The pyrazolopyrimidines PP1 and PP2* and the 4-anilinoquinazoline Vandetanib inhibit RET-rearrangement-derived oncoproteins with a half maximal inhibitor concentration (IC50) below 100 nM. These molecules were shown to inhibit RET enzymatic activity and phosphorylation of downstream targets, such as ERK1/2. Vandetanib has also been found to inhibit RET signalling in two human PTC cell lines and to reduce tumorigenicity of *RET*/*PTC*-transformed fibroblasts injected into nude mice \[[@B50]\]. Vandetanib blocks *in vivo* phosphorylation and signalling mediated by RET/PTC3 oncoprotein and of an epidermal growth factor- (EGF-) activated EGF-receptor/RET chimeric receptor. Finally, it blocks anchorage-independent growth of *RET/PTC3*-transformed NIH3T3 fibroblasts and the formation of tumors after injection of NIH-*RET/PTC3* cells into nude mice \[[@B51]\].

*Sorafenib (BAY 43-9006)* was designed originally as a RAF inhibitor \[[@B61]\]. Nonetheless, preclinical studies have shown that Sorafenib can inhibit the kinase activity and signalling of wild-type and oncogenic RET. Sorafenib inhibited oncogenic RET kinase activity at an IC50 of 50 nM or less in NIH3T3 cells. It arrested the growth of NIH3T3 and RAT1 fibroblasts transformed by oncogenic RET and of thyroid carcinoma cells that harbour rearranged RET alleles. These inhibitory effects paralleled a decrease in RET phosphorylation \[[@B57]\]. Finally, PTC cells carrying the *RET/PTC1* rearrangement were found to be more sensitive to Sorafenib than PTC cells carrying a *BRAF* mutation \[[@B62]\]. There is an ongoing phase II clinical trial using Sorafenib in patients with advanced thyroid cancer \[[@B63]\].

*RPI-1* is a 2-indolinone derivative initially shown to inhibit RET/PTC1 activity in an immunokinase assay with an IC50 of 27--42 *μ*M. It selectively inhibited the anchorage-independent growth of NIH3T3-transformed cells expressing the *RET/PTC1* gene, and the transformed phenotype of NIH3T3ptc1 cells was reverted to a normal fibroblast-like morphology. In these cells, the constitutive tyrosine phosphorylation of RET/PTC1, of the transducing adaptor protein Shc, and of a series of co-immunoprecipitated peptides was substantially reduced \[[@B52]\]. Activation of JNK2 and AKT was abolished, thus supporting the drug inhibitory efficacy on downstream pathways. In addition, cell growth inhibition was associated with a reduction in telomerase activity by nearly 85% \[[@B64]\].

*Sunitinib* was initially described as a TKI targeting VEGF and PDGFR receptors \[[@B65]\] and also found to inhibit c-KIT \[[@B66]\]. It is now approved for the treatment of GIST and renal cell carcinoma. *In vitro* kinase assays showed that Sunitinib inhibited the phosphorylation by RET/PTC3 of a synthetic tyrosine kinase substrate peptide in a dose-dependent manner. RET/PTC-mediated Y705 phosphorylation of STAT3 was inhibited by addition of Sunitinib, and the inhibitory effects of Sunitinib on tyrosine phosphorylation and transcriptional activation of STAT3 very closely correlated with decreased autophosphorylation of RET/PTC. Sunitinib caused a complete morphological reversion of transformed NIH-*RET/PTC3* cells and inhibited the growth of TPC-1 cells that have an endogenous *RET/PTC1* \[[@B55]\]. Treatment of two patients with progressive metastatic thyroid carcinoma (1 PTC and 1 FTC) demonstrated sustained clinical responses to Sunitinib over a period of four years \[[@B67]\].

*Gefitinib* was initially approved for nonsmall cell lung cancer since it targets oncogenic EGFR. *In vitro* data suggests that EGFR contributes to RET kinase activation, signalling, and growth stimulation. Conditional activation of RET/PTC oncoproteins in thyroid PCCL3 cells markedly induced expression and phosphorylation of EGFR, which was mediated in part through mitogen-activated protein (MAP) kinase signalling. RET and EGFR were found to co-immunoprecipitate. Ligand-induced activation of EGFR resulted in phosphorylation of a kinase-dead RET, and this effect was entirely blocked by EGFR kinase inhibitor. Gefitinib also inhibited cell growth induced by various constitutively active mutants of *RET* in thyroid cancer cells as well as in NIH3T3 cells \[[@B56]\]. These pieces of evidence have provided a biological basis for clinical evaluation of Gefitinib in thyroid cancer. The results obtained in a phase II trial showed no objective responses among the 25 thyroid cancer patients treated with Gefitinib \[[@B68]\].

*CEP-701 and CEP-751* are indolocarbazole derivatives that also inhibit RET in MTC cells. Effective inhibition of RET phosphorylation in a dose-dependent manner is achieved at concentrations \<100 nM. These compounds also block the growth of MTC cells in culture. CEP-751 and its prodrug, CEP-2563 inhibit tumor growth in MTC cell xenografts \[[@B53]\]. These drugs also potentiate the effects of irinotecan treatment in TT cell culture and xenografts and result in durable complete remission in 100% of the mice. CEP-751 inhibited the induction of the DNA repair program (marked by phospho-H2AX) as well as the checkpoint pathway (marked by the activated Chk1) \[[@B69]\]. Since preclinical models have demonstrated that both CEP-751 and CEP-2563 have antitumor activity in a variety of tumors, phase I trials were undertaken \[[@B70]\].

Several other TKI molecules are being evaluated with regard to their efficacy in metastatic MTC treatment with limited published data. *Axitinib*(AG-013736) \[[@B71]\] was assessed in a phase II study with 60 MTC patients. Eighteen cases (30%) presented partial responses, and 23 (38%) had stable disease \[[@B59]\]. *Motesanib* (AMG706) \[[@B72]\] was evaluated in differentiated thyroid cancer \[[@B58]\] and in a phase I study in 91 patients with either hereditary (16 cases) or sporadic MTC (75 cases), 2% of the patients showed partial response, and 81% had stable disease \[[@B73]\]. *XL184/XL880* is a compound that is rapidly going through the clinical evaluation process. It is a TKI that targets VEGFR2, RET, and also MET and whose efficacy has been demonstrated for several solid tumors, especially thyroid cancer \[\*\*\*\]. In patients with hereditary and sporadic MTC very interesting response rates were obtained with 9/17 patients (53%) showing partial remission. Based on these findings, a phase III registration trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) has been initiated.

7. The Influence of Genotype on the Sensitivity to RET-Targeting TkIs and Challenges Ahead {#sec7}
==========================================================================================

Although a number of patients with refractory MTC have been undergoing treatment with several TKIs in the last few years, it is not yet clear whether clinical response to these drugs is actually influenced by the *RET* genotype of the tumor cells. At this point, the only reliable source for this type of information comes from *in vitro* studies. Indeed, some compounds used against RET seem to confirm the paradigm that certain mutations can render RET resistant to inhibition. This was first illustrated by PP1, PP2, and ZD6474 (Vandetanib) which, despite being efficient in inhibiting phosphorylation of most of the MEN2-associated *RET* mutants (at codons 768, 790, 883, 918, and 634 \[[@B50]\]), were incapable of inhibiting MEN2-associated swap of Valine 804 for bulky hydrophobic Leucine or Methionine within the RET kinase domain. Thus Valine 804 emerged as a structural determinant amino acid mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines \[[@B74], [@B75]\]. This was also found to be the case for the V804M/E805K tandem lesion, detected in non-Met918/Ala883 MEN2B, which was shown to also confer resistance to PP1, suggesting a mode of action different from the classical MEN2B mutations \[[@B33]\].

However, inhibition of RET phosphorylation and signaling by mutation of the Val804 gatekeeper residue was not impaired in cells subjected to Sorafenib treatment \[[@B76]\], indicating that this drug could be a potential therapeutic tool for *RET* Val804 positive thyroid tumors \[[@B76]\].

The fact that using another compound can overcome a mutation-specific primary resistance renders further support to the idea that sensitivity of *RET* mutants will, in the end, result from mutation-dependent structural determinants of the RET ATP-binding site. However, to support the paradigm of an *RET* pharmacogenetics, much more needs to be evaluated before we can confirm that this concept is useful for the clinical practice. To start, it would be imperative that the mutation status of the tumors from patients included in clinical trials is ascertained and correlated with clinical response. Until now, none of the clinical studies have published the mutation status of the patients. On the other hand, we must not forget that despite the *in vitro* data has proven highly informative for genotype/phenotype correlations, it cannot be taken directly to indicate differences in terms of clinical response. In addition, many of these small molecule inhibitors act upon several target RTKs, rendering it difficult to ascertain which of the effects over different RTKs actually accounts for the observed clinical response.

We should also be aware that some of the effects of these compounds may go beyond interference with the ATP-binding pocket and may affect RET expression. For instance, Sorafenib suppresses RET tyrosine kinase activity by direct enzymatic inhibition and also by promoting RET lysosomal degradation independent of proteasomal targeting \[[@B76]\].

At this point, given that a number of molecules are starting to become available, it would be worth to compare these drugs against each other in their efficacy to inhibit the activity of the most frequent *RET* genotypes. This may come as a means to define and stratify drugs for use as first-line and second-line treatments on the basis of the *RET* genotype.

As we highlighted before, specific *RET* mutations may lead stronger induction of specific intracellular signalling targets, many of which have their own dedicated inhibitors under development. In this respect, the information about the specificities in oncogenic signalling of different genotypes might be valuable to design combinatorial therapies employing mutation-specific combinations of inhibitors for treatment.

At present, the clinical use of tyrosine kinase inhibitors in patients with thyroid cancer still does not rely in the genetic background of each tumor \[[@B63], [@B59], [@B77]\]. Nonetheless, results from clinical trials suggest that these compounds have a more cytostatic than cytolytic effect, and thus are just adding another step of selective pressure to the progressing tumor (which buys time), but eventually secondary resistance can develop. In models such as *ABL/CML* (imatinib), *EGFR*/lung cancer (Gefitinib), or *KIT*/GIST (imatinib), prolonged therapy with TKIs leads to the acquisition of resistance mutations in the receptors targeted by these drugs, rendering them insensitive to therapy. Although no secondary *RET* mutations have been described thus far, the experience with patients undergoing clinical trials taught that some patients suddenly fail to respond while on treatment. Most probably, the same underlying resistance mechanisms are at play. This implies that, in order to translate the use of these inhibitors into increased long-term survival, we may need to perform molecular followup of the progressing lesions, in order to predict resistance and eventually change from one inhibitor to another.

Finally, to reduce the biology of MTC to *RET* activation and signaling boosting is almost certainly a simplistic view. RET mutations do not only determine MTC development (even in hMTC). Likely these tumours also carry mutations in other genes, and possibly one should also know these to think about combinatory therapies. Indeed, data is accumulating regarding alternative pathways that contribute to MTC development from precursor C-cell hyperplasia. This is the case of the WNT pathway activation by RET-mediated tyrosine phosphorylation of *β*-Catenin \[[@B11]\] and the synergistic effects of p18 and p27, two members of the RB pathway \[[@B78], [@B79]\]. This may provide additional targets for combination of RET inhibitors with other compounds targeting these pathways. Also relevant to this is the recent recognition of mechanisms of cross-talk between different RTKs. For instance, EGFR may cooperate with RET in activating intracellular signaling pathways \[[@B56]\]. This provides biological basis for combining different RTK inhibitors.

The challenge for the years to come is to use the pools of knowledge generated in RET signaling pathways and MTC progression steps to rationalize combinatory therapies, targeting different molecules and different signaling pathways that are relevant in MTC.
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###### 

Molecules used in preclinical and clinical trials as RET tyrosine kinase inhibitors.

  Compound      Trade name              Structure            Targets                                               Clinical trials   Refs
  ------------- ----------------------- -------------------- ----------------------------------------------------- ----------------- --------------------
  PP1           Zaleplon                Pyrazolopyrimidine   RET                                                   ---               \[[@B50]\]
  PP2                                                                                                                                
                                                                                                                                     
  ZD6474        Vandetanib              Anilinoquinazoline   RET; VEGFR; EGFR                                      Phase II          \[[@B51]\]
                                                                                                                                     
  RPI-1         ---                     Indolinone           RET; MET                                              ---               \[[@B52]\]
                                                                                                                                     
  SU5416        Sunitinib               Butanedioic acid     VEGFR-2; PDGFR; c-KIT; RET; CSF-1R                    Phase II          \[[@B55], [@B67]\]
  SU11248                                                                                                                            
                                                                                                                                     
  ZD1839        Gefitinib               Anilinoquinazoline   EGFR                                                  Phase II          \[[@B56], [@B68]\]
                                                                                                                                     
  BAY43-9006    Sorafenib               Bis-aryl urea        RAF-1; BRAF; VEGFR-2/-3; PDGFR-B; Flt-3; c-KIT; RET   Phase II          \[[@B57], [@B63]\]
                                                                                                                                     
  AMG706        Motesanib diphosphate   Diphosphate salt     VEGFR; PDGFR; KIT; RET                                Phase II          \[[@B58], [@B73]\]
                                                                                                                                     
  AG-013736     Axitinib                Benzamide            RET; VEGFR; PDGFR; c-KIT                              Phase II          \[[@B59]\]
                                                                                                                                     
  XL184/XL880                                                VEGFR2; RET and MET                                   Phase III         \[\*\*\*\]

\[\*\*\*\] Eder et al. \[[@B80]\]. LoRusso et al. \[[@B81]\]. Ross et al. \[[@B82]\]. Salgia et al. \[[@B83]\].
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